BerandaSYGGF • OTCMKTS
add
Synairgen Ord Shs
Tutup sebelumnya
$0,0085
Rentang tahun
$0,0085 - $0,090
Kapitalisasi pasar
11,03 jt GBP
Volume Rata-Rata
2,89 rb
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (GBP) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 1,95 jt | -29,14% |
Laba bersih | -1,63 jt | 31,28% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -1,95 jt | 28,75% |
Tarif pajak efektif | 10,92% | — |
Neraca
Total aset
Total liabilitas
| (GBP) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 8,59 jt | -19,19% |
Total aset | 10,64 jt | -43,12% |
Total liabilitas | 1,08 jt | -60,69% |
Total ekuitas | 9,56 jt | — |
Saham yang beredar | 201,37 jt | — |
Harga terhadap nilai buku | 0,17 | — |
Tingkat pengembalian aset | -45,90% | — |
Tingkat pengembalian modal | -51,07% | — |
Arus Kas
Perubahan kas bersih
| (GBP) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -1,63 jt | 31,28% |
Kas dari operasi | -1,84 jt | 30,36% |
Kas dari investasi | 882,00 rb | 88.100,00% |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | -962,50 rb | 63,64% |
Arus kas bebas | -1,13 jt | 24,89% |
Tentang
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Didirikan
2003
Situs
Karyawan
36
